6 ms·
> The sales and marketing departments in most companies are more powerful than their R&D departments. Yes, this is correct. > Hence, the design, conduct, rep
by ekianjo 7y ago
> The sales and marketing departments in most companies are more powerful than their R&D departments.
Yes, this is correct.
> Hence, the design, conduct, reporting, and dissemination of this clinical evidence becomes an advertisement tool.
This does not follow well logically. The design of clinical trials still belongs to R&D and not Marketing/Sales departments. Even if Marketing/Sales want to target for a specific outcome, there is nothing saying that this particular outcome will be met until you actually try it clinically. And specific outcomes are usually desirable outcomes: for example, showing that your drug is non just superior to placebo, but superior to the current best-in-class treatment. Or measuring patient-related outcomes that are tied to economic value (for example, making a patient recover faster has tangible societal benefits - they can come back to work, be an active family member, etc...) is also relevant these days.
So, there is not a strong link between "pushing for an outcome that you can advertise" and "this outcome being clinically meaningless". If it were meaningless, FDAs and other regulatory bodies would not even accept it during the clinical trial design review phase.
> As for basic research
Basic research should be the responsibility of academics, not companies. And they do. But not many academics focus on "checking whether what we have been using for 20 years really works", there's too much priority on new clinical targets.
- Alex3917 7y ago> This does not follow well logically. Instead of trying to reason from first principles about whether or not what he's saying is true, maybe instead go on Amazon and buy one of the dozens of books on the subject.
- wallace_f 7y agoI don't know if what he is saying is true, but I do know from having worked in another industry that the idea of sales/marketing dictating product development is not necessarily illogical, even if at face value it is.
- marcus_holmes 7y agoin a lot of industries, Sales/Marketing dictating product development is the default. Sales and Marketing folks get used to that kind of power... and then they transfer to a new industry.
- RobertRoberts 7y ago> If it were meaningless, FDAs and other regulatory bodies would not even accept it during the clinical trial design review phase. Go look up how many corporate stooges are in the place in the FDA over the years. A good starting point is the history of Aspartame, I'd link some articles, but I suspect the sources would be shot down and evidence ignored. The people at the FDA were complicit in its approval, despite scientific evidence showing it was dangerous.
- abrichr 7y agoI would appreciate links to articles on the subject, if you have them handy!
- Alex3917 7y agoThe tl;dr is that the same guys who fabricated the evidence about Saddam Hussein having WMDs also fabricated evidence for aspartame being safe. https://www.huffpost.com/entry/donald-rumsfeld-and-the-s_b_805581 https://www.huffpost.com/entry/donald-rumsfeld-and-the-s_b_8...
- deleted 7y ago[deleted]
- ben_w 7y agoDid Donald Rumsfeld also convince the European Union, who have their own interests and a similar sized economy, that it was safe? https://www.efsa.europa.eu/en/press/news/131210 https://www.efsa.europa.eu/en/press/news/131210 or the “more than 90 countries worldwide” [1] that the Canadian government refers to on their own website? https://www.canada.ca/en/health-canada/services/food-nutrition/food-safety/food-additives/sugar-substitutes/aspartame-artificial-sweeteners.html https://www.canada.ca/en/health-canada/services/food-nutriti... There are certainly cases where I don’t trust USA regulations. This just isn’t one of them. [1] number includes EU and US, but that still leaves more than sixty others.
- 7y ago
- BurningFrog 7y ago> This does not follow well logically I think it's an observation, not a philosophical argument.
- ekianjo 7y agoNo, he said "Hence," right at the start of the sentence, as if it was a logical conclusion. It is not.
- PeterStuer 7y agoSales and Marketing do control which outcomes are allowed to be published though. If you allow me selective disclosure of trials I can show you that my roulette strategy is infallible.
- viraptor 7y agoHasn't this been fixed with the requirement to pre-register trials? https://chrisblattman.com/2016/03/01/13719/ https://chrisblattman.com/2016/03/01/13719/ I'm not sure if every org requires it now or not, but if not then it seems like a question of time only.
- hannob 7y ago> Hasn't this been fixed with the requirement to pre-register trials? If it was that simple... Preregistration is a step in the right direction, but there are still plenty of ways to game the system, particularly as it's not properly enforced: http://compare-trials.org/ http://compare-trials.org/
- ekianjo 7y agoBut it is the necessary step to highlight the problem so that actions can be taken. Also, you can safely assume that the large majority of outcomes that were not published were:\ - negative - worse than negative (i.e. safety issues?) - not properly designed So if you compare the number of trials disclosed/not disclosed for each drug/each company that gives you a pretty good picture of who is doing what already. With that data, it's then a lot easier to approach regulators to do something about it.
- tomp 7y agoMy assumption is that most unpublished trials were "no effect". Be a drug company. Develop a "drug" that is really a placebo (has no effect). Do 10 trials. 8 are "no effect", 1 is positive (by chance), 1 is negative (by cance). Publish the positive drug. Market the drug as having positive effect. Sell the drug, make billions. It would take decades for enough other research (mostly "no effect") to accumulate before it becomes obvious that your drug actually has no effect.
- wazoox 7y agoUntil recently, Big Pharma CEOs were either medical doctors of pharmacists. Marketing and finance were important, but not a driving force. Nowadays all of Big Pharma is headed by bean counters, marketing drones and finance guys, and are only interested in EBITDA. This is the main problem in all industries were science and engineering once prevailed.
- shadowtree 7y agoReally? Novartis - former head of R&D. Pfizer - PhD in Veterinary Medicine (he joined their AH division in 93) Astra Zeneca - Veterinary too Merck / MSD - Lawyer Roche - Economics & Law Gilead - Biology abbvie - never went to college, 30 years at company Amgen - Biology
- nabla9 7y ago> If it were meaningless, FDAs and other regulatory bodies would not even accept it during the clinical trial design review phase. Billions in R&D goes to getting molecular entities approved by FDA that are clinically meaningless. The medical R&D is done just to get a product that provides already existing functionality or already existing treatment with a slightly modified molecule that can be patented. It's like the joke about man who goes to patent office and says that he invented gunpowder. Patent clerk says that unfortunately gunpowder has already been invented. The man says: "But I invented more of it." Approval process is not looking if the new drug is meaningful improvement over existing drugs. "Inventing more of the same" is approved if it can be tweaked a little to be unique. Alternative is also true. There are potentially clinical treatments and medicines that receive no approvals because there is no profit motive to push them trough the expensive process of approval.
- galangalalgol 7y agohow do they get doctors to prescribe the patented versions if they aren't better?
- mattmcknight 7y agoSometimes they pay other companies not to make the unpatented drug: https://www.ftc.gov/news-events/media-resources/mergers-competition/pay-delay https://www.ftc.gov/news-events/media-resources/mergers-comp... More tricks here: https://hbr.org/2017/04/how-pharma-companies-game-the-system-to-keep-drugs-expensive https://hbr.org/2017/04/how-pharma-companies-game-the-system...
- kyokpae 7y agoSales reps bribe doctors, plain and simple. https://www.vice.com/en_us/article/pg7ez9/pharma-reps-are-basically-bribing-your-doctor-study-confirms https://www.vice.com/en_us/article/pg7ez9/pharma-reps-are-ba...
- deleted 7y ago[deleted]
- 7y ago
- rjkennedy98 7y ago> The design of clinical trials still belongs to R&D and not Marketing/Sales departments. This is FALSE. It's literally come out in court documents. https://www.motherjones.com/environment/2010/09/dan-markingson-drug-trial-astrazeneca/ https://www.motherjones.com/environment/2010/09/dan-markings... > In 1997, when Dr. Andrew Goudie, a psychopharmacologist at the University of Liverpool, asked AstraZeneca to fund a research study he was planning, a company official replied that “R&D is no longer responsible for Seroquel research—it is now the responsibility of Sales and Marketing.” The official also noted that funding decisions would depend on whether the study was likely to show a “competitive advantage for Seroquel.”
- ChrisLomont 7y ago>This is FALSE. How do you demonstrate that one case implies all cases?
- rjkennedy98 7y agoThis isn't a small company nor is it a minor drug. This is one of the largest drug companies running a trial on one of the most lucrative drugs in the world. And secondly, why should ANY drug trial be managed by a PR department? When you ask people to risk their lives to be in a drug trial (in the link above the subject died in the trial), why should it be to improve the PR of a drug for one company. The fact that this exists at all is a major warning sign. The indifference of people to this is frankly amazing to me (its even worse than the disinformation provided by the OP).